護城河比較

Narrow, not wide, because the FY2026 10-K documents a strong installed base and a competitive position the company itself says is under erosion. On the asset side: revenue of $4.7 billion (29% growth in each of the last three fiscal years), 13,328 total customers up from 10,996, 790 of the Forbes Global 2000 contributing about 43% of revenue, 733 customers above $1 million in trailing-12-month product revenue up from 576, a 125% net revenue retention rate, and more than 1,050 issued U.S. patents. Against that, Item 1A states plainly that adopting open data formats like Apache Iceberg means 'there is less customer “lock in” when our products are used in external environments' and that 'our support of open data formats may also reduce switching costs between us and our competitors'; that AWS, Azure and GCP 'generally compete in all of our markets' while also supplying the infrastructure a 'substantial majority of our business is run on'; and that the company remains loss-making at $1.3 billion of net loss for the year.

來源：sec.gov

Argued, not assumed. The FY2025 10-K does evidence a real moat in margin: total gross margin percentage rose 44.1% (2023) to 46.2% (2024) to 46.9% (2025) in markets the same filing describes as characterised by 'aggressive price competition, downward pressure on gross margins.' But the filing bounds the claim itself: it concedes 'a minority market share in the global smartphone, personal computer, tablet and wearables markets,' it discloses no retention, active-device or installed-base figure anywhere (its only 'large installed bases of active devices' reference describes competitors), and it discloses that both of the highest-margin layers are already being cut down by force -- Apple is 'currently subject to a court order preventing it from imposing any commission or fee on certain purchases' on the U.S. App Store storefront, has had to open 'alternative methods of distribution for iOS and iPadOS apps, alternative payment processing' in the EU, and warns that a reversal on appeal in the Google search case could impose remedies 'prohibiting Google from offering the Company commercial terms for search distribution.' A moat that earns 46.9% gross margin but whose most profitable layer is being narrowed by two courts and a regulator is narrow, not wide.

來源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

來源：sec.gov

The filing makes its own affirmative claim of network effects — 'Our business benefits from powerful network effects. ... The more customers adopt our platform, the more data can be exchanged with other Snowflake customers, partners, data providers, and data consumers' — but the load-bearing, quantified evidence in the document points to switching costs. The platform is sold as the way to 'consolidate data into a single source of truth,' and the disclosed economics of that consolidation are a 125% net revenue retention rate and 733 customers above $1 million in trailing product revenue. Item 1A confirms the mechanism by naming what is at risk: open formats produce 'less customer “lock in”' and 'may also reduce switching costs.' The filing frames lock-in, not network density, as the thing erosion would take away.

來源：sec.gov

The 10-K locates the durable advantage in an integrated stack and its third-party ecosystem, not in patents: it names 'a strong third-party software and accessories ecosystem' among the principal competitive factors and states the Company 'designs and develops nearly the entire solution for its products, including the hardware, operating system, numerous software applications and related services,' while explicitly disclaiming IP as the source -- 'No single intellectual property right is solely responsible for protecting the Company's products and services' and the Company 'relies primarily on the innovative skills, technical competence and marketing abilities of its personnel.' The remedies now in force confirm the diagnosis negatively: the same filing describes being required to permit alternative distribution and alternative payment processing in the EU and being barred from charging commission on certain linked-out purchases in the U.S. -- remedies aimed squarely at lowering the cost of leaving Apple's rails, which is what a switching-cost moat is.

來源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

來源：sec.gov

The 10-K contains no ranking, market-share figure, or claim of leadership, and it names no non-hyperscaler competitor by name. The band rests on disclosed scale — $4.7 billion of revenue, 13,328 customers, 9,060 employees across 36 countries — set against the filing's own statement that 'many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical, and other resources than we do.' Co-leader among independent cloud data platforms; not a leader over AWS, Azure and GCP, which the filing says compete in all of its markets.

來源：sec.gov

Apple leads on integration and margin rather than on units, and the filing says so: it 'has a minority market share in the global smartphone, personal computer, tablet and wearables markets,' while competitors have 'broad product lines, low-priced products, large installed bases of active devices, and large customer bases.' On the AI axis that defines this graph, Apple is following rather than leading -- it now licenses a rival's frontier models to power Siri (see the Apple Intelligence / Siri row and its citation) while pushing its own advantage down into silicon.

來源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

來源：sec.gov

The consumption model plus 125% net revenue retention shows real expansion pricing, and the filing argues it competes on 'pricing transparency and optimized price-performance.' But Item 1A limits how far that goes: competition 'may negatively impact our ability to acquire new customers ... put downward pressure on our prices and gross margins'; the company 'may not be able to ... offer as many discounts or free services as our competitors'; results depend on 'changes in our pricing model, including in response to significant price discounts by our competitors' and on 'customer optimization efforts that result in reduced consumption.' On the cost side, 'our costs and gross margins are significantly influenced by the prices we are able to negotiate with these public cloud providers, which in certain cases are also our competitors.'

來源：sec.gov

The 10-K's own gross-margin table: total gross margin percentage 44.1% (2023) to 46.2% (2024) to 46.9% (2025), with Services at 75.4% versus Products at 36.8%, and iPhone net sales rising 'due to higher net sales of Pro models' -- mix moving up, not down. Held against the filing's own hedge that 'gross margins will be subject to volatility and downward pressure,' the realised trend is the stronger evidence.

來源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

來源：sec.gov

Sits at the enterprise data and governance layer of the AI stack, and the AI exposure is explicit rather than incidental: the filing brands the product the 'AI Data Cloud,' lists AI as a product category, and put Snowflake Intelligence, Cortex Agents and a Managed MCP Server into general availability during the fiscal year. It is a buyer of hyperscaler compute and of third-party frontier models — 'strategic partnerships with foundational model providers deliver state-of-the-art models natively within Snowflake Cortex AI,' with stated 'model neutrality' — and a supplier of governed enterprise data and GPU-backed managed compute to AI applications built on top.

Applications-layer name in the AI chain: the 10-K describes designing 'nearly the entire solution' and using custom components 'available from only one source,' making Apple a large, concentrated buyer of leading-edge silicon rather than a supplier of AI compute to anyone else.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• Analytics 前三 · 深 來源：sec.gov
• Data Engineering 挑戰者 · 中等 來源：sec.gov
• Snowflake Cortex AI 挑戰者 · 中等 來源：sec.gov
• Snowflake Marketplace and Data Collaboration 領先 · 深 來源：sec.gov
• Snowflake Postgres and Unistore 利基市場 · 低 來源：sec.gov
• Snowpark and Native Application Framework 利基市場 · 中等 來源：sec.gov

• App Store and iOS app distribution 領先 · 中等 來源：ec.europa.eu
• Apple Intelligence and Siri 挑戰者 · 低 來源：finance.yahoo.com
• Apple silicon (A-series and M-series SoCs) 未知 · 深 來源：apple.com
• Apple-designed cellular modem (C1) 未知 · 中等 來源：apple.com
• Mac 挑戰者 · 中等 來源：sec.gov
• Search placement licensing (Google default search) 未知 · 低 來源：9to5mac.com
• Services 領先 · 中等 來源：sec.gov
• Wearables, Home and Accessories 前三 · 中等 來源：sec.gov
• iPad 前三 · 中等 來源：sec.gov
• iPhone 前三 · 深 來源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 來源：sec.gov
• Spikevax 前三 · 中等 來源：sec.gov
• mNEXSPIKE 前三 · 中等 來源：sec.gov
• mRESVIA 挑戰者 · 中等 來源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →